Richter's transformation (RT) refers to the development of an aggressive lymphoma in patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia. Studies have shown that 2-10 % of patients with CLL develop RT including diffuse large B-cell lymphoma (DLBCL) and less commonly Hodgkin lymphoma (HL). This study aims to assess the risk factors for RT of CLL in a nationwide cohort. Additionally, we want to examine risk factors for death in patients with RT. The findings in this study may guide management of treated as well as untreated patients with CLL in risk of RT.
Multivariate models of risk factors will be performed.
• Predefined analyses according to published protocol.
• Methodological challenges to conduct research in this area.
•
Confounding effects of socioeconomic status, ethnical, dietary and geographical differences on RT development will not be adjusted for.
DANRICHT -Risk factors associated with Richter's transformation in patients with chronic lymphocytic leukaemia: protocol for a retrospective population-based cohort study INTRODUCTION Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in adults (1) . Approximately 400 people are diagnosed with CLL in Denmark each year with increasing incidence (2) . CLL is characterised by a heterogeneous disease course where some patients require initial treatment, while about 40% remain untreated (2) . Patients with CLL can be stratified into four different risk groups: Low, intermediate, high, or very high risk based on the CLL international prognostic index (CLL-IPI). Despite an improved prognosis following the introduction of new targeted therapy and chemo-immunotherapy (1), Richter's Transformation (RT) still affects about 2-10 % of patients with CLL (3) (4) (5) . RT, defined as the transformation of CLL or small lymphocytic lymphoma into an aggressive lymphoma (diffuse large B-cell lymphoma (DLBCL) or Hodgkin's lymphoma (HL)) is one of the most severe complications associated with CLL (3, 4, 6, 7) . The median time from the CLL diagnosis until RT occurs to lie in the range of two to four years (3, 7, 8) .
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For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   2 Rarely, some patients are diagnosed with RT at the time of CLL diagnosis (1) . The clinical course of RT is aggressive with a reported median survival of 1-2 years (9) (10) (11) . Risk factors of transformation may differ from risk factors of CLL progression (10) . Therefore, RT may not necessarily be predicted from studies of CLL. Previous studies have identified clinical (Binet stage B / C, performance status, lymphadenopathy), biochemical (lactate dehydrogenase (LDH) elevation), biological (unmutated IGHV, expression of CD38 and ZAP70) and genetic ( del(13q) absence), trisomy 12 (Tri12)), del(11q) and del(17p) are associated with an increased risk of RT (Table 1) (7, 8, 10, 12) . Recently, studies have identified distinct genetic mechanisms by which CLL transforms into an aggressive lymphoma. Disruption of TP53, NOTCH1 and CDKN2A, as well as c-MYC activation were associated with development of RT (3, 7) . It is still controversial if CLL therapy (purinenucleoside analogue and/or targeted therapy) affects the risk of RT (8, 11) . Nevertheless, early transformation upon targeted therapy is a concern for physicians as well as patients with aggressive CLL (13) . As these patients may possibly benefit from alternative therapeutic strategies including intensive chemo-immunotherapy and allogeneic stem cell transplantation, it is important to identify patients with increased risk of RT before initiating CLL therapy (12, 14) .
Research questions
1. What is the incidence of RT in a nationwide cohort? 2. Are we able to confirm risk factors already identified in previous studies? 3. Can we identify novel risk factors for development of RT? 4. Does treatment affect development of RT? 5. How do these risk factors impact overall survival?
METHODS AND ANALYSIS

Study design
The study protocol for identification of patients with RT, data collections and data analyses are summarised in Figure 1 .
Patients and public involvement
All patients in the Danish CLL Registry (DCLLR) between 2008 and 2016 were included. This includes patients with CLL diagnosis according to the International Workshop on CLL (IWCLL) criteria, a Danish address and a valid personal identification number. It is mandatory for all hospitals to report CLL patients in this registry. Therefore, this registry comprises data on all patients diagnosed in Denmark, including date of birth, gender, date of death, treatment regimens and risk factors (7, 13) .
Patients identified from DCLLR with a concomitant biopsy proven diagnosis of DLBCL and/or HL from the Danish National Pathology Data Bank (Patobank) is considered to have RT and will be included in this study. Patobank is a national histopathology and cytopathology register founded in 1978 and is now nationwide (15) . SNOMED codes included in this study are summarised in Table 2 .
A strategy for collecting information on RT patients will consist of a double-controlled reading. Once the initial reading of a patient chart is completed, the second reading will be performed independently by another researcher to verify the collected data.
Statistical analysis plan:
Patients will be followed from the date of CLL diagnosis until the date of RT, death or end of follow-up, whichever comes first. The statistical analysis in this study will be based on baseline characteristics where we will examine three time points. 1) In the time from CLLdiagnosis to diagnosis of RT, risk factors (Table  1) will be investigated to determine their impact on CLL transformation. 2) From time of initiating treatment to time of RT diagnosis, we will investigate the impact of treatment on the risk of development of RT in treated as well as untreated CLL patients. 3) From RT diagnosis to death, we will measure the influence of the risk factors on the overall prognosis of RT. Descriptive analysis of all possible risk factors (Table 1 ) will be performed. For continuous variables, the mean, standard deviation or median and IQR values will be reported according to distribution. The categorical data will be presented with frequency tables (n, %). The Aalen-Johansen estimator will be used for cumulative incidence. The Kaplan-Meier method will be used for overall survival. Log-rank and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   3 Gray's test will be used to test differences between groups. CLL patients without RT obtained from the DCLLR will represent our control group. The data from this control group will be compared with data from our RT-patients collected from Patobank. Cox-models for multivariate analysis will be performed with backward elimination. Statistical significance will be defined as a P-value of less than 0.05. All data manipulation, visualization and statistical analysis will be performed with R (16).
DISCUSSION
RT is one of the most severe complications of CLL. The previously published retrospective studies have identified clinical, biochemical, biological as well as genetic characteristics in CLL patients to be important risk factors of RT (7, 8, 10, 11) . Our study will be the first nationwide study to investigate the incidence of RT and analyse the impact of risk factors in multivariate analyses. Moreover, we will be able to assess if different treatment regimens are associated with higher risk of RT, thus answering important questions in our understanding of RT.
Strengths
The key strength of our study is the nationwide setup, with a consecutive cohort of more than 4000 CLL patients and a predefined analysis plan and protocol. The Danish unique identification number enables us to merge registry data to ensure a complete follow-up in an unselected real world CLL population (17,18). We expect to find a total of 80-200 RT patients, enabling us to assess multiple factors for both risk of RT and survival following RT. In contrast, single centre studies often represent data with a risk of selection-bias towards a higher socioeconomic status, hence a healthier patient cohort (19) . This cohort will ensure a high coverage of all patients diagnosed with CLL within the nine-year period (2), due to the cross validation of DCLLR with other registries. Through a manual, double-controlled assessment of medical records, we will assess multiple risk factors in association to outcomes. The data assembly from medical records will ensure information on both patient-specific and diseasespecific variables, as well as information on treatment variables and response to treatment. The crossed reading of the medical records ensures a complete data collection, thus minimizing the amount of missing information. With this approach, our outcomes are expected to add further evidence to existing knowledge on potential risk factors identified so far.
Limitations
To address research questions in rare complications to rare cancers, prospective studies are not always feasible. Thus, knowledge concerning risk factors predicting RT in CLL patients is limited. Retrospective studies are therefore necessary to determine the risk factors. These studies are often susceptible to methodological bias and chance findings, which is also a major limitation of our study. Even though DCLLR is highly validated, we cannot fully exclude selection bias in our study (17). We must consider that some haematological departments have a more thorough registration than others, even though the cross validation with other health registries aim to minimise any selection bias. Due to limited information on socioeconomic status as well as ethnical, dietary patterns and geographical differences, the impact of such on RT cannot be addressed in this study. Flowchart of the study design From time of CLL diagnosis, estimates of cumulative incidence of RT will be calculated using the Aalen-Johansen estimator. From time of RT diagnosis, survival analysis will be performed by Kaplan-Meier method. Cox proportional hazards models will be used for multivariable survival analysis.
Ethics and dissimilation Approvals for data collection and analysis was obtained from the Danish Data Protection Agency and the Danish Health Authorities. All data will be managed confidentially according to guidelines and legislation. The dissemination will include a publication of scientific papers and/or presentations of the study findings at international conferences. (3, 7, 8) . Rarely, some patients are diagnosed with RT at the time of CLL diagnosis (1). The clinical course of RT is aggressive with a reported median survival of 1-2 years (9-11). Risk factors of transformation may differ from risk factors of CLL progression (10) . Therefore, RT may not necessarily be predicted from studies of CLL. Previous studies have identified clinical (Binet stage B / C, performance status, lymphadenopathy), biochemical (lactate dehydrogenase (LDH) elevation), biological (unmutated IGHV, expression of CD38 and ZAP70) and genetic ( del(13q) absence), trisomy 12 (Tri12)), del(11q) and del(17p) are associated with an increased risk of RT (Table 1) (7, 8, 10, 12) . Recently, studies have identified distinct genetic mechanisms by which CLL transforms into an aggressive lymphoma. Disruption of TP53, NOTCH1 and CDKN2A, as well as c-MYC activation were associated with development of RT (3, 7) .
INTRODUCTION
Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in adults (1).
Strengths and Limitations
It is still controversial if CLL therapy (purinenucleoside analogue and/or targeted therapy) affects the risk of RT (8, 11) . Nevertheless, early transformation upon targeted therapy is a concern for physicians as well as patients with aggressive CLL (13) . As these patients may possibly benefit from alternative therapeutic strategies including intensive chemoimmunotherapy and allogeneic stem cell transplantation, it is important to identify patients with increased risk of RT before initiating CLL therapy (12, 14) .
Research questions
1. What is the incidence of RT in a nationwide cohort? 2. Are we able to confirm risk factors already identified in previous studies? 3. Can we identify novel risk factors for development of RT? 4. Does treatment of CLL affect development of RT? 5. How do these risk factors impact overall survival?
METHODS AND ANALYSIS
Study design
The study protocol for identification of patients with RT, data collections and data analyses are summarised in Figure 1 . (15) . SNOMED codes included in this study are summarised in Table 2 .
Patients and public involvement
Statistical analysis plan:
Patients will be followed from the date of CLL diagnosis until death or end of follow-up, whichever comes first. The statistical analysis in this study will be based on baseline characteristics where we will examine three time points. 1) In the time from CLL-diagnosis to diagnosis of RT, risk factors will be investigated to determine their impact on RT (Table 1) .
2) From time of initiating treatment to time of RT diagnosis, we will investigate the impact of CLL treatment on the risk of development of RT.
3) From RT diagnosis to death, we will measure the influence of the risk factors on the overall prognosis of RT. Descriptive analysis of all possible risk factors (Table 1 ) will be performed. For continuous variables, the mean, standard deviation or median and IQR values will be reported according to distribution. The categorical data will be presented with frequency tables (n, %). The Aalen-Johansen estimator will be used for cumulative incidence. The Kaplan-Meier method will be used for overall survival. Log-rank and Gray's test will be used to test differences between groups. CLL patients without RT obtained from the DCLLR will represent our control group. The data from this control group will be compared with data from our RT-patients collected from Patobank. Cox-models for multivariable analysis will be performed with backward elimination. Statistical significance will be defined as a Pvalue of less than 0.05. All data manipulation, visualization and statistical analysis will be performed with R (16).
DISCUSSION
RT is one of the most severe complications of CLL. The previously published retrospective studies have identified clinical, biochemical, biological as well as genetic characteristics in CLL patients to be important risk factors of RT (7, 8, 10, 11) . Our study will be the first nationwide study to investigate the incidence of RT and analyse the impact of risk factors in multivariable analyses. Moreover, we will be able to assess if different treatment regimens are associated with higher risk of RT, thus answering important questions in our understanding of RT.
Strengths
The key strength of our study is the nationwide setup, with a consecutive cohort of more than 4000 CLL patients and a predefined analysis plan and protocol. The Danish unique identification number enables us to merge registry data to ensure a complete follow-up in an unselected real world CLL population (17,18). We expect to find a total of 80-200 RT patients, enabling us to assess multiple factors for both risk of RT and survival following RT. In contrast, single centre studies often represent data with a risk of selection-bias towards a higher socioeconomic status, hence a healthier patient cohort (19) . This cohort will ensure a high coverage of all patients diagnosed with CLL within the nineyear period (2), due to the cross validation of DCLLR with other registries. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Through a manual, double-controlled assessment of medical records, we will assess multiple risk factors in association to outcomes. The data assembly from medical records will ensure information on both patient-specific and disease-specific variables, as well as information on treatment variables and response to treatment. The crossed reading of the medical records ensures a complete data collection, thus minimizing the amount of missing information. With this approach, our outcomes are expected to add further evidence to existing knowledge on potential risk factors identified so far. Investigation of the clonal relationship is of high clinical importance. Recent studies have shown that the clonal relationship between DLBCL and the underlying CLL has critical prognostic implications in RT (20) . However, the question concerning clonal relationship between DLBCL cells and the pre-existing or concomitant CLL remains unanswered. In this respect, a possible follow-up study using tissue samples from Patobank, is essential to determine the prognostic impact of clonal status in RT patients. Studies examining clonality and genetic associations to RT are therefore needed for researching possible novel treatment targets in patient at high risk of RT. We suggest implementing a high degree of screening and careful, long-term monitoring programs at Departments of Haematology to identify CLL patients harbouring relevant risk factors. High risk of RT when dealing with CLL patients, may influence the patient counselling, making patients more aware of systemic symptoms which facilitates an early diagnosis of RT. By promptly detecting RT in these patients, we expect a more favourable prognosis, both because of the aggressiveness of this transformation but also since more targeted and individualized treatment strategies can be employed.
Limitations
To address research questions in rare complications to rare cancers, prospective studies are not always feasible. Thus, knowledge concerning risk factors predicting RT in CLL patients is limited. Retrospective studies are therefore necessary to determine the risk factors. These studies are often susceptible to methodological bias and chance findings, which is also a major limitation of our study. Even though DCLLR is highly validated, we cannot fully exclude selection bias in our study (17). We must consider that some haematological departments have a more thorough registration than others, even though the cross validation with other health registries aim to minimise any selection bias. Due to limited information on socioeconomic status as well as ethnical, dietary patterns and geographical differences, the impact of such on RT cannot be addressed in this study.
Despite the limitations, this protocol describes an approach to enable further testing of evidence concerning risk factors and outcomes of RT. We aim to establish clinically significant risk factors that can potentially guide the management of patients with CLL. With this approach, our outcomes are expected to add further evidence to existing knowledge on potential risk factors identified so far. The results from this study may be used to create a risk model to stratify patients with RT into high, intermediate and low risk of death using clinical, biochemical, biological and genetic risk factors. Hereby, we can generate a stratifying system with potential implications on medical practices.
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INTRODUCTION
Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in adults (1) . Approximately 400 people are diagnosed with CLL in Denmark each year with increasing incidence (2). CLL is characterised by a heterogeneous disease course where some patients require initial treatment, while about 40% remain untreated (2). Patients with CLL can be stratified into four different risk groups: Low, intermediate, high, or very high risk based on the CLL international prognostic index (CLL-IPI). Despite an improved prognosis following the introduction of new targeted therapy and chemo-immunotherapy (1), Richter's Transformation (RT) still affects about 2-10 % of patients with CLL (3-5). RT, defined as the transformation of CLL or small lymphocytic lymphoma into an aggressive lymphoma (diffuse large B-cell lymphoma (DLBCL) or Hodgkin's lymphoma (HL)) is one of the most severe complications associated with CLL (3,4,6,7) . The median time from the CLL diagnosis until RT occurs to lie in the range of two to four years (3, 7, 8) . Rarely, some patients are diagnosed with RT at the time of CLL diagnosis (1). The clinical course of RT is aggressive with a reported median survival of 1-2 years (9-11). Risk factors of transformation may differ from risk factors of CLL progression (10) . Therefore, RT may not necessarily be predicted from studies of CLL. Previous studies have identified clinical (Binet stage B /
Strengths and Limitations
• Largest study to date on RT including a nationwide cohort of approximately 4,000 CLL patients with an expected prevalence of 80-200 RT-patients.
•
Multivariable models of risk factors will be performed.
• Confounding effects of socioeconomic status, ethnical, dietary and geographical differences on RT development will not be adjusted for.
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For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   3 C, performance status, lymphadenopathy), biochemical (lactate dehydrogenase (LDH) elevation), biological (unmutated IGHV, expression of CD38 and ZAP70) and genetic ( del(13q) absence), trisomy 12 (Tri12)), del(11q) and del(17p) are associated with an increased risk of RT (Table 1) (7, 8, 10, 12) . Recently, studies have identified distinct genetic mechanisms by which CLL transforms into an aggressive lymphoma. Disruption of TP53, NOTCH1 and CDKN2A, as well as c-MYC activation were associated with development of RT (3, 7) . It is still controversial if CLL therapy (purinenucleoside analogue and/or targeted therapy) affects the risk of RT (8, 11) . Nevertheless, early transformation upon targeted therapy is a concern for physicians as well as patients with aggressive CLL (13) . As these patients may possibly benefit from alternative therapeutic strategies including intensive chemoimmunotherapy and allogeneic stem cell transplantation, it is important to identify patients with increased risk of RT before initiating CLL therapy (12, 14) . 
Research questions
METHODS AND ANALYSIS
Study design
The study protocol for identification of patients with RT, data collections and data analyses are summarised in Figure 1 . (15) . SNOMED codes included in this study are summarised in Table  2 .
Patient identification
Patients and public involvement
Involvement of all Danish CLL patients will be ensured through nationwide registries. Since data will be collected in a retrospective manner, the CLL patients are unable to participate and engage directly in this current study. Our research results concerning risk factors for RT will broaden the understanding of RT amongst CLL patients. This may potentially cause national and local health changes, that directly responds to the concerns and real-life experiences of CLL patients. By gathering data, evidence and knowledge in this study, direct influence on haematologists' understanding of RT in CLL subjects may modify national guidelines. New insights into the barriers of RT may develop approaches that researchers can utilize when handling additional aspects of CLL patients in risk of RT. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Statistical analysis plan:
Patients will be followed from the date of CLL diagnosis until death or end of follow-up, whichever comes first. The statistical analysis in this study will be based on baseline characteristics where we will examine three time points. 1) In the time from CLL-diagnosis to diagnosis of RT, risk factors will be investigated to determine their impact on RT (Table 1) . 2) From time of initiating treatment to time of RT diagnosis, we will investigate the impact of CLL treatment on the risk of development of RT.
DISCUSSION
Strengths
The key strength of our study is the nationwide setup, with a consecutive cohort of more than 4000 CLL patients and a predefined analysis plan and protocol. The Danish unique identification number enables us to merge registry data to ensure a complete follow-up in an unselected real world CLL population (17,18). We expect to find a total of 80-200 RT patients, enabling us to assess multiple factors for both risk of RT and survival following RT. In contrast, single centre studies often represent data with a risk of selection-bias towards a higher socioeconomic status, hence a healthier patient cohort (19) . This cohort will ensure a high coverage of all patients diagnosed with CLL within the nineyear period (2), due to the cross validation of DCLLR with other registries. Through a manual, double-controlled assessment of medical records, we will assess multiple risk factors in association to outcomes. The data assembly from medical records will ensure information on both patient-specific and disease-specific variables, as well as information on treatment variables and response to treatment. The crossed reading of the medical records ensures a complete data collection, thus minimizing the amount of missing information. With this approach, our outcomes are expected to add further evidence to existing knowledge on potential risk factors identified so far. Investigation of the clonal relationship is of high clinical importance. Recent studies have shown that the clonal relationship between DLBCL and the underlying CLL has critical prognostic implications in RT (20) . However, the question concerning clonal relationship 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   5 between DLBCL cells and the pre-existing or concomitant CLL remains unanswered. In this respect, a possible follow-up study using tissue samples from Patobank, is essential to determine the prognostic impact of clonal status in RT patients. Studies examining clonality and genetic associations to RT are therefore needed for researching possible novel treatment targets in patient at high risk of RT. We suggest implementing a high degree of screening and careful, long-term monitoring programs at Departments of Haematology to identify CLL patients harbouring relevant risk factors. High risk of RT when dealing with CLL patients, may influence the patient counselling, making patients more aware of systemic symptoms which facilitates an early diagnosis of RT. By promptly detecting RT in these patients, we expect a more favourable prognosis, both because of the aggressiveness of this transformation but also since more targeted and individualized treatment strategies can be employed.
Limitations
Despite the limitations, this protocol describes an approach to enable further testing of evidence concerning risk factors and outcomes of RT. We aim to establish clinically significant risk factors that can potentially guide the management of patients with CLL. With this approach, our outcomes are expected to add further evidence to existing knowledge on potential risk factors identified so far. The results from this study may be used to create a risk model to stratify patients with RT into high, intermediate and low risk of death using clinical, biochemical, biological and genetic risk factors. Hereby, we can generate a stratifying system.
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